Literature DB >> 24321399

A distinctive ovarian cancer molecular subgroup characterized by poor prognosis and somatic focal copy number amplifications at chromosome 19.

Chang Ohk Sung1, In-Hye Song2, Insuk Sohn3.   

Abstract

OBJECTIVE: High-grade serous ovarian cancer (HGS-OvCa), the most common epithelial ovarian cancer, is very complex and heterogeneous at the molecular level. The identification of intrinsic HGS-OvCa subgroups characterized by specific molecular alterations and aggressive behavior could improve patient treatment.
METHODS: High-resolution copy number data for 560 HGS-OvCa patients and gene expression data obtained from the TCGA database were analyzed to identify distinct molecular subgroups based on significant focal somatic copy number alterations (SCNAs).
RESULTS: Using unsupervised consensus clustering, a subgroup accounting for 26.8% of the patients (150/560 patients) characterized by focal somatic copy number amplification at chromosome 19 was identified. The subgroup was independently associated by multivariate Cox regression analysis with poor overall (HR, 1.61; P = 0.001) and progression-free survival (HR, 1.36; P = 0.036). The specific focal SCNA locations were 19p13.2, 19p13.12, 19p13.11, 19q12, 19q13.12, and 19q13.2. The differential gene expression signature of the subgroup compared with that of the remaining patients also suggested that chromosome 19 was the mainly amplified region. The clinical significances of subgroup 2 were validated in independent data sets using the gene expression signature characteristics. In addition, the subgroup had a tendency toward mutual exclusivity with patients with BRCA1/2 mutations. The most significantly altered pathway of the subgroup was the cyclin and cell cycle regulation pathway.
CONCLUSION: A unique molecular subgroup associated with poor survival was identified based on focal SCNAs and could aid the further molecular classification of ovarian cancers.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Carcinoma; Clustering; Copy number; Ovary; Prognosis; Serous

Mesh:

Substances:

Year:  2013        PMID: 24321399     DOI: 10.1016/j.ygyno.2013.11.036

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  8 in total

Review 1.  Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells.

Authors:  Ugo Testa; Eleonora Petrucci; Luca Pasquini; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2018-02-01

Review 2.  [Grading of gynecological tumors : Current aspects].

Authors:  L-C Horn; D Mayr; C E Brambs; J Einenkel; I Sändig; K Schierle
Journal:  Pathologe       Date:  2016-07       Impact factor: 1.011

3.  Genomic characteristics in neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.

Authors:  Wenwu He; Xuefeng Leng; Kangning Wang; Tiaoqin Mao; Lin Peng; Qiang Fang; Wenguang Xiao; Yongtao Han
Journal:  J Gastrointest Oncol       Date:  2020-12

4.  Genome-wide association analysis reveals variants on chromosome 19 that contribute to childhood risk of chronic otitis media with effusion.

Authors:  Elisabet Einarsdottir; Lena Hafrén; Eira Leinonen; Mahmood F Bhutta; Erna Kentala; Juha Kere; Petri S Mattila
Journal:  Sci Rep       Date:  2016-09-16       Impact factor: 4.379

Review 5.  The role of distinct BRD4 isoforms and their contribution to high-grade serous ovarian carcinoma pathogenesis.

Authors:  Ana Luiza Drumond-Bock; Magdalena Bieniasz
Journal:  Mol Cancer       Date:  2021-11-10       Impact factor: 27.401

6.  FXYD5 is a Marker for Poor Prognosis and a Potential Driver for Metastasis in Ovarian Carcinomas.

Authors:  Pichai Raman; Timothy Purwin; Richard Pestell; Aydin Tozeren
Journal:  Cancer Inform       Date:  2015-10-12

7.  Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.

Authors:  Meiyuan Chen; Min Wang; Simiao Xu; Xingjun Guo; Jianxin Jiang
Journal:  Oncotarget       Date:  2015-12-29

8.  BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors.

Authors:  Garrett W Rhyasen; Yi Yao; Jingwen Zhang; Austin Dulak; Lillian Castriotta; Kelly Jacques; Wei Zhao; Farzin Gharahdaghi; Maureen M Hattersley; Paul D Lyne; Edwin Clark; Michael Zinda; Stephen E Fawell; Gordon B Mills; Huawei Chen
Journal:  PLoS One       Date:  2018-07-23       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.